{"groups":[{"description":"ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.","id":"FG000","title":"ACZ885"},{"description":"Placebo subcutaneous injection every 8 weeks.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}],"type":"Unsatisfactory therapeutic effect"}],"milestones":[{"achievements":[{"comment":"All patients received treatment with ACZ885 in Part I of the study.","groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"comment":"Only patients with a complete response completed Part I and entered Part II of the study.","groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Part I - Open-label Treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"12"}],"type":"Unsatisfactory therapeutic effect"}],"milestones":[{"achievements":[{"comment":"Patients with complete response to treatment entered Part II and were randomized to ACZ885 ,placebo.","groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"16"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"12"}],"type":"NOT COMPLETED"}],"title":"Part II - 1:1 ACZ885:Placebo"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Unsatisfactory therapeutic effect"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"comment":"All patients received treatment with ACZ885 in Part III of the study.","groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Part III - Open-label Treatment Period"}]}